Navigation Links
Cystic Fibrosis Foundation President Rings Bell to Close New York Stock Exchange
Date:5/13/2008

Federal Realty Investment Trust invites Foundation to celebrate scientific advancements that have fueled longer life for people with CF

BETHESDA, Md., May 13 /PRNewswire-USNewswire/ -- To celebrate remarkable progress in treating cystic fibrosis -- a fatal genetic disease -- Federal Realty Investment Trust invited the Cystic Fibrosis Foundation to join the company as honored guests of the New York Stock Exchange (NYSE) today.

Life expectancy for people with CF has more than doubled in the past 25 years, as a result of scientific advances fueled by the Foundation. When the Foundation was established in 1955, few children with the disease lived to attend elementary school. Today, the median predicted age of survival for people with CF is 37 years.

In recognition of the Foundation's achievements and National CF Awareness Month, Robert J. Beall, Ph.D., president and CEO of the Foundation and Donald Wood, president and CEO of Federal Realty Investment Trust, rang the NYSE bell signaling the close of the market at 4:00 P.M today.

"We are pleased and honored to take part in this distinguished NYSE tradition," said Beall. "People with cystic fibrosis are living longer than ever, and we are excited about this tremendous progress. At the same time, there is much work to be done in the fight against this devastating disease."

To advance the search for a cure, the Foundation has built a "pipeline of promise" with more than 30 therapies in development for cystic fibrosis, and invested nearly $300 million in CF research in the biotech industry since 1998. For the first time in the history of the disease, the Foundation's pipeline has drugs under development that target the root causes of cystic fibrosis -- not just the symptoms. If successful, these therapies will add decades of life for people with CF.

Virtually every approved CF drug available today was made possible because of Foundation support. Since the 1980s, the Foundation has played an integral role in the development of Pulmozyme, TOBI, azithromycin and hypertonic saline for use as CF treatments.

"This is truly an exciting time for the CF community, with so many promising therapies in development," said Federal Realty Investment Trust president and CEO Donald Wood. "We are more passionate than ever about the Foundation's critical work to cure and control cystic fibrosis."

Federal Realty Investment Trust is an equity real estate investment trust specializing in the ownership, management, development, and redevelopment of high quality retail assets. Federal Realty is an S&P MidCap 400 company and its shares are traded on the NYSE under the symbol FRT.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization in the United States devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation has more than 80 chapters and branch offices throughout the country and supports and accredits a nationwide network of 115 care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit http://www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
3. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
4. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
5. Cystic Fibrosis foundation lays out new treatment guidelines
6. Experts Release New Cystic Fibrosis Guidelines
7. Lung Transplants May Not Help Most Cystic Fibrosis Children
8. Ibuprofen associated with slower lung function decline in children with cystic fibrosis
9. Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis
10. Montana Passes Newborn Screening Law for Cystic Fibrosis
11. Cystic Fibrosis Foundation reports upward trend for key health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing designer ... stand solutions representative to the Minneapolis Home and Garden Show which is being held ... is garnering national attention is the Minneapolis Convention Center. , From its broad ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... certification exam and eligibility requirements effective with the April 2017 testing period. NACCM, ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... analytics to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, ... This new solution helps transform the HCC Risk Adjustment process from a ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic ... 9.2% over the next decade to reach approximately $8.9 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
Breaking Medicine Technology: